NAV
Explore a selection of essential drug information below, or:
Unlock enhanced features & extensive drug insights. Create a free account.
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Melitracen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Explore a selection of our essential drug information below, or:

CREATE FREE ACCOUNT
Full Drug Profiles
Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.
SUBSCRIBERECOMMENDED FOR PHARMA
Data Packages
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Summary

Melitracen is a thioxanthene neuroleptic indicated in the treatment of anxiety, depression, and asthenia.

Generic Name
Melitracen
DrugBank Accession Number
DB13384
Background

Not Available

Type
Small Molecule
Groups
Experimental, Investigational
Structure
3D
Similar Structures
Weight
Average: 291.438
Monoisotopic: 291.198699809
Chemical Formula
C21H25N
Synonyms
  • Melitracen
  • Melitraceno
Get Early Access To DrugBank+
Be among the first to try our new AI-powered, game-changing platform. DrugBank+ is here to streamline your pharmaceutical research and deliver faster insights and smarter decisions.
Join the Waitlist
Get Early Access To DrugBank+
Join the Waitlist

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatAnxietyCombination Product in combination with: Flupentixol (DB00875)••••••••••••••••••
Used in combination to treatDepressionCombination Product in combination with: Flupentixol (DB00875)••••••••••••••••••
Used in combination to treatSchizophrenia and other psychotic disordersCombination Product in combination with: Flupentixol (DB00875)••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available
Unlock the secrets to drugging the undruggable
Discover how groundbreaking research is turning "undruggable" targets into therapeutic opportunities.
Download eBook
Unlock the secrets to drugging the undruggable
Download eBook

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Melitracen.
AcarboseMelitracen may decrease the hypoglycemic activities of Acarbose.
AcebutololMelitracen may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of gastrointestinal bleeding can be increased when Melitracen is combined with Aceclofenac.
AcemetacinThe risk or severity of gastrointestinal bleeding can be increased when Melitracen is combined with Acemetacin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ANXISETMelitracen (10 MG) + Flupentixol (0.5 MG)Tablet, film coatedOralบริษัท ยูเนียนเมดดิคอล (ประเทศไทย) จำกัด2014-06-13Not applicableThailand flag
DEANXITMelitracen (10 MG) + Flupentixol (0.5 MG)Tablet, sugar coatedOralบริษัท บี.เอ็ล.ฮั้ว จำกัด1985-02-13Not applicableThailand flag
Deanxit - FilmtablettenMelitracen (10 mg) + Flupentixol (0.5 mg)Tablet, film coatedOralLundbeck Inc.1971-01-13Not applicableAustria flag
DEANXIT TABLETMelitracen (10 mg) + Flupentixol (0.5 mg)Tablet, film coatedOralLundbeck Inc.1988-09-05Not applicableSingapore flag
DORMIR TABLET, 20 ADETMelitracen (10 mg) + Flupentixol (0.5 mg)TabletOSEL İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag

Categories

ATC Codes
N06CA02 — Melitracen and psycholepticsN06AA14 — Melitracen
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as anthracenes. These are organic compounds containing a system of three linearly fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Anthracenes
Sub Class
Not Available
Direct Parent
Anthracenes
Alternative Parents
Trialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Amine / Anthracene / Aromatic homopolycyclic compound / Hydrocarbon derivative / Organic nitrogen compound / Organonitrogen compound / Organopnictogen compound / Tertiary aliphatic amine / Tertiary amine
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Q7T0Y1109Z
CAS number
5118-29-6
InChI Key
GWWLWDURRGNSRS-UHFFFAOYSA-N
InChI
InChI=1S/C21H25N/c1-21(2)19-13-7-5-10-17(19)16(12-9-15-22(3)4)18-11-6-8-14-20(18)21/h5-8,10-14H,9,15H2,1-4H3
IUPAC Name
[3-(10,10-dimethyl-9,10-dihydroanthracen-9-ylidene)propyl]dimethylamine
SMILES
CN(C)CCC=C1C2=CC=CC=C2C(C)(C)C2=CC=CC=C12

References

General References
  1. FDA Thailand Product Information: Anxiset (melitracen/flupentixol) film-coated tablets [Link]
ChemSpider
23697
BindingDB
112783
RxNav
446248
ChEBI
135214
ChEMBL
CHEMBL110094
ZINC
ZINC000001482101
Wikipedia
Melitracen

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
Not AvailableUnknown StatusNot AvailableGastro-esophageal Reflux Disease (GERD)1somestatusstop reasonjust information to hide
Not AvailableUnknown StatusNot AvailableSomatic Symptom Disorders1somestatusstop reasonjust information to hide
Not AvailableUnknown StatusTreatmentAntidepressant Discontinuation Syndrome / Antidepressant Drug Adverse Reaction / Dyspepsia / Functional Gastrointestinal Disorders (FGID)1somestatusstop reasonjust information to hide
4CompletedTreatmentCompliance / Depression / Dyspepsia1somestatusstop reasonjust information to hide
4CompletedTreatmentEmotional Disorders / Neurological Disorders1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, sugar coatedOral
Tablet
Tablet
Tablet, film coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00318 mg/mLALOGPS
logP5.4ALOGPS
logP4.95Chemaxon
logS-5ALOGPS
pKa (Strongest Basic)9.76Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count1Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area3.24 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity116.42 m3·mol-1Chemaxon
Polarizability36.16 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0a4i-9070000000-a1b11cf6767a87110b94
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0007-0090000000-29a4b986e4bb3b5a0532
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0090000000-d0c810d7f6105f5e1967
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0005-0090000000-88e45c17fc2caa64fbcb
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0090000000-dbb90842e7b0b2dd93db
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-06di-1490000000-e6804aaddcf20e733f1a
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0gb9-0090000000-f65b81ca7f1d58043ce1
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-184.684326
predicted
DarkChem Lite v0.1.0
[M-H]-168.24065
predicted
DeepCCS 1.0 (2019)
[M+H]+185.698426
predicted
DarkChem Lite v0.1.0
[M+H]+170.59863
predicted
DeepCCS 1.0 (2019)
[M+Na]+185.183126
predicted
DarkChem Lite v0.1.0
[M+Na]+176.69176
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:41 / Updated at June 02, 2021 20:04